MITEMCINAL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C40H69NO12
Molecular Weight	755.9754
Optical Activity	UNSPECIFIED
Defined Stereocenters	16 / 16
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C(C)C)[C@@]4(C)CC(C)=C(O4)[C@H](C)C(=O)[C@]1(C)OC

InChI

InChIKey=BELMMAAWNYFCGF-PZXAHSFZSA-N

InChI=1S/C40H69NO12/c1-16-28-40(12,47-15)33(43)23(6)31-21(4)18-39(11,53-31)35(52-37-30(42)27(17-22(5)48-37)41(13)20(2)3)24(7)32(25(8)36(45)50-28)51-29-19-38(10,46-14)34(44)26(9)49-29/h20,22-30,32,34-35,37,42,44H,16-19H2,1-15H3/t22-,23+,24+,25-,26+,27+,28-,29+,30-,32+,34+,35-,37+,38-,39-,40-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C40H69NO12
Molecular Weight	755.9754
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	16 / 16
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17785940 | https://www.ncbi.nlm.nih.gov/pubmed/17894654 | https://www.ncbi.nlm.nih.gov/pubmed/11566017

Mitemcinal (GM-611), an erythromycin-derived prokinetic agent, was developed by Chuga as an agonist of the motilin receptor. Mitemcinal acts by a novel mechanism whereby it stimulates and promotes peristalsis in the stomach and other segments of the gastrointestinal tract. This drug was studied as a potential treatment for gastric motility disorder, as well as reflux esophagitis, non-ulcer dyspepsia, and diabetic gastroparesis. Mitemcinal was involved in phase II clinical trials in Patients with diabetic gastroparesis. Although gastroparetic symptoms improved with both mitemcinal and placebo, the prominent placebo effect was not statistically exceeded by mitemcinal. That is why the development of this drug has stalled. In addition, mitemcinal has been studied in phase II for the treatment of irritable bowel syndrome, but this study was also discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Motilin receptor 3 Target ID: O43193 Gene ID: 2862.0 Gene Symbol: MLNR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17785940	Agonist 2752

PubMed

Title	Date	PubMed
Phase II drugs under clinical investigation for the treatment of chronic constipation.	2014-11	24960333
Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study.	2007-10-15	17894654
Hemodynamic and electrophysiological effects of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin in a halothane-anesthetized canine model.	2007-08	17785940
Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.	2007-08	17785939

Patents

Sample Use Guides

In Vivo Use Guide

12 weeks of treatment with oral tablets given twice a day of GM-611 (Mitemcinal) 5mg, 10mg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:59:12 GMT 2025` Edited by `admin` on `Wed Apr 02 08:59:12 GMT 2025`
Record UNII	6X5NRJ664L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MITEMCINAL

Official Name

English

8,9-DIDEHYDRO-N-DEMETHYL-9-DEOXO-6,11-DIDEOXY-6,9-EPOXY-N-ISOPROPYL-12-O-METHYL-11-OXOERYTHROMYCIN

Preferred Name

English

mitemcinal [INN]

Common Name

English

Mitemcinal [WHO-DD]

Common Name

English

ERYTHROMYCIN, 8,9-DIDEHYDRO-N-DEMETHYL-9-DEOXO-6,11-DIDEOXY-6,9-EPOXY-12-O-METHYL N-(1-METHYLETHYL)-11-OXO-

Common Name

English

Code System Code Type Description

WIKIPEDIA

MITEMCINAL